Ready To Get Started?
Contact us to discuss licensing therapeutic assets or initiating a discovery partnership.
Or call (215) 966-6061
Therapeutic Pipeline
See our preclinical pipeline, including assets available to license. Licensing models can range from straight-out licensing to ongoing joint research.
Preclinical Pipeline
Target
Indication
Modality
Discovery
Preclinical
Phase 1
License Status
CLDN18.2
solid tumors
ADC
Undisclosed
SLC2A4
undisclosed
undisclosed
Undisclosed
CLDN18.2
solid tumors
ADC
Preclinical
Undisclosed
SLC2A4
undisclosed
undisclosed
Preclinical
Undisclosed
TCE: T-cell engager (multi-specific antibody)
ADC: Antibody-drug conjugate
CAR-T: Chimeric antigen receptor T cell
Assets Available to License
Monoclonal antibody assets are available against the following targets. Assets for additional undisclosed targets are in the discovery phase. All antibody assets are exclusively owned by Integral Molecular and were discovered using our MPS Antibody Discovery platform.
- CLDN18.2 x CD3 T cell engager for gastric and pancreatic cancer
- GPCR5D x CD3 T cell engager for multiple myeloma
- CCR8 for immuno-oncology
- P2X3 for chronic cough and chronic pain
- P2X7 for autoimmune conditions
Integral is open to, and has concluded, a variety of licensing models, from straight-out licensing to ongoing joint research. We have flexibility to adjust to what works best for both parties.
The Integral Advantage: Best-in-class MAbs
We’ve developed antibodies against certain targets because they’re generally regarded as promising. And we’re not the only ones to have done so. But there are a few reasons to think ours are better than the rest.
Learn more about our industry-leading MPS Antibody Discovery Platform
“Integral Molecular have been outstanding partners in enabling us to advance our lead molecule CTIM-76 towards IND. They developed an antibody with unrivaled selectivity for CLDN6, an absolute requirement for safely and effectively targeting solid tumors.”
Therapeutic Asset Partners
Learn more about our current partnerships:
More Ways to Work Together: Explore our Related Technologies
MAb Discovery Partnerships
You have a promising biotherapeutic target, but you need support in developing a therapeutic against it.
We can help. From custom antigen design to delivery of preclinical leads ready for IND-enabling studies, we’re your partner.
Our industry-leading antibody discovery platform has a 95%+ success rate generating MAbs against even the most challenging membrane protein targets.
Target Discovery Partnerships
Discover novel therapeutic targets using our Membrane Proteome Array™ (MPA) platform.
The MPA has 6,000 human membrane proteins expressed on unfixed human cells. It is not only the leading solution for antibody specificity profiling, it also identifies potential new targets through functional assays.
